|
Volumn 7, Issue 4, 2001, Pages 314-320
|
Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease
a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
HEPATITIS B SURFACE ANTIBODY;
HEPATITIS B SURFACE ANTIGEN;
HEPATITIS B VACCINE;
HLA ANTIGEN;
RECOMBINANT VACCINE;
ADOLESCENT;
ADULT;
AGE;
AGED;
ANTIBODY TITER;
ARTICLE;
CALCULATION;
CHILD;
CLINICAL TRIAL;
CONCENTRATION (PARAMETERS);
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DRUG DOSE;
DRUG EFFICACY;
DRUG RESPONSE;
FEMALE;
FOLLOW UP;
GENETIC PREDISPOSITION;
HEPATITIS B;
HEPATITIS B VIRUS;
HEPATITIS C;
HLA TYPING;
HUMAN;
INFANT;
LIVER FAILURE;
LIVER TRANSPLANTATION;
MAJOR CLINICAL STUDY;
MALE;
PREDICTION;
PREVALENCE;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
PROTECTION;
RETROSPECTIVE STUDY;
SCORING SYSTEM;
SEROCONVERSION;
VACCINATION;
|
EID: 0035051731
PISSN: 15276465
EISSN: None
Source Type: Journal
DOI: 10.1053/jlts.2001.23069 Document Type: Article |
Times cited : (84)
|
References (30)
|